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Recommendations for anticoagulation following major venous reconstruction for pancreatic adenocarcinoma (PA) are not clearly
established. The aim of our study was to ﬁnd out the relation between postoperative anticoagulant treatment and thrombosis rate
a f t e rp o r t a lv e n o u sr e s e c t i o n .Materials and methods. Between 1986 and 2006, twenty seven portal vein resections were performed
associated with pancreaticoduodenectomies (n = 27) (PD).We deﬁned four types of venous resection: type I was performed 1cm
above the conﬂuent of the superior mesenteric vein (SMV) (n = 12); type II lateral resection and venorrhaphy at the level of the
conﬂuent SMV (n = 12); type III (n = 1) resulted from a primary end-to-end anastomosis above conﬂuent and PTFE graph was
used for reconstruction for type IV (n = 2). Curative anticoagulant treatment was always indicated after type IV (n = 2) resection,
and after resection of type II when the length of venous resection was longer than ≥2cm.Results. Venous thrombosis rate reached:
0%, 41%, and 100% for type I, II, IV resections, respectively. Among them four patients received curative anticoagulant treatment.
Conclusion.AfteraportalveinresectionwasachievedinthecourseofaPD,curativepostoperativeanticoagulationdoesnotprevent
eﬃciently the onset of thrombosis.
Copyright © 2008 Mehdi Oua¨ ıssi et al. Thisisan open access articledistributedunder theCreative CommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Resection of pancreatic duct adenocarcinoma has a high
mortality rate [1]. Surgery still remains the only curative
treatment, and tumoral invasion of the portal vein is
not a contraindication of resection. Several techniques of
venous resection and reconstruction have been described,
such as primary lateral resection and venorrhaphy, primary
circumferential resection with end-to-end anastomosis or
graft interposition [2]. Recommendations for anticoagula-
tion following major venous reconstruction for malignancy
are not clearly established.
The aim of our study was to ﬁnd out a relation between
postoperative anticoagulant treatment and thrombosis por-
tal rate after mesentericoportal segmental venous resection.
2. MATERIALS AND METHODS
From January 1996 to December 2006, 500 pancreatic resec-
tions were performed with curative intents in two surgical
digestive departments. Twenty seven portal vein resections
were performed in the course of a pancreaticoduodenectomy
(PD).Clinicopathologic ﬁndings wereanalyzedtodetermine
f a c t o r sw h i c ha r ea b l et oa ﬀect rates of morbidity and2 Gastroenterology Research and Practice
Table 1: Types of resection and anticoagulation treatment associated with complications (hemorrhagic, thrombosis) and mortality rates.
Type I
PV
SV
VMS
Type II
PV
SV
VMS
Type III
PV
SV
VMS
Type IV
PV
SV
VMS
Preoperative treatment Type I (n = 12) Type II (n = 12) Type III (n = 1) Type IV (n = 2)
Preventive anticoagulation 10 (83%) 8 (66%) 1 (100%) 0 (0%)
Curative anticoagulation 2 (17%) 4 (34%) 0 (0%) 2 (100%)
Median resection size (cm) 1.5 (2–4) 1 (1–4) 3 4.5
Thrombosis (%) 0 (0%) 5 (41%) 0 (0%) 2 (100%)
Hemorrhage (%) 0 (0%) 3 (25%) 0 (0%) 1 (50%)
Mortality rate (%) 0 (0%) 2 (16%) 0 (0%) 1 (50%)
thrombosis in relation with venous reconstruction and
anticoagulation treatment.
2.1. Operativetechnique
Contrast-enhanced computed tomography has been the
most useful imaging exams to determine local respectability
[3, 4]. When adherence to the lateral or posterior wall of
the portal vein was encountered, surgeons preferred venous
resection.
2.2. Pancreaticresection
Dissectionofretroperitonealmarginwascarriedoutpriorto
the venous resection. Aims of this technical choice were to
avoid the need of venous anastomosis prior to the removal
of the specimen to limit duration of venous occlusion and
to allow as far as possible a preservation of the splenic vein.
This was done either by a large kocher manoeuvre or by
isolation of the superior mesenteric artery (SMA) both at
its origin and the uncinate process. Kocher’s manoeuvre
oriented the SMA posterior to the portal vein and superior
venousmesenteric andallowedaneasyaccessforcompletion
of the retroperitoneal dissection. Arterial branches coursing
into the uncinate were sequentially clamped, divided, and
ligated. Complete liberation of the pancreas from the SMA
was done in the early course of the operation. The pancreatic
head was then rotated back to its normal orientation; venous
resection was performed as the ﬁnal step of the resection.
2.3. Resectionandvenousreconstruction
Vascular control was always obtained proximally and distally
taking care to isolate the superior mesenteric vein (SMV),
portalvein(PV),andsplenicvein(SV).Controlofthegastric
vein was sometimes required. We did not perform SMA
occlusion because the duration of the clamping period of
the PV was always less than 20 minutes. Type of resection
is summarized in Table 1. A wedge resection was performed
in case of limited ingrowths; elsewhere segmental resection
was achieved when venous ingrowths appeared to be more
extensive.
W ed e ﬁ n e df o u rt y p e so fv e n o u sr e s e c t i o n :( 1 )i n
type I, lateral resection and venorrhaphy of portal were
performed; these resections were realized >1cm above the
SMV conﬂuent (n = 12); (2) in type II, lateral resection
and venorrhaphy of SMV and PV conﬂuent were performed
(n = 12); (3) in type III, a primary end-to-end anastomosis
abovetheSMVandPVconﬂuentwasperformed(n = 1);(4)
in type IV, a circumferential resection (length >3cm) of the
SMV and PV conﬂuent was carried out and PTFE graph was
used for reconstruction (n = 2). Reimplantation of SV was
never achieved in case of type IV resection.
2.4. Anticoagulanttreatment
Curative anticoagulant treatment was always indicated for
type IV (n = 2) resections and in four cases (30%) of
type II resections when the length of venous resection
was ≥2cm. Curative anticoagulant was based on systemic
anticoagulation therapy by heparin systemic anticoagulation
therapy by Heparin (500unit/kg/day) was indicated for 10
days in order to increase the activated partial thromboplastin
time to 1.5–2.0 times that of control and then the treatment
was discontinued at day 8. The oral anticoagulation drug
(with antivitamine K) was given after control CT scan at day
8 to raise the mean international normalization ratio (INR).
T h er a t eo fI N Rw a sb e t w e e n2 . 5a n d3a n dt h et r e a t m e n t
was performed during three months. Other patients had
preventive anticoagulation by low molecular weight heparin.
2.5. Clinicalandradiologicalfollowup
All patients beneﬁted from angiographic CT scan on day 7.
Diagnosisofvenousocclusionwassettledonclinicalﬁndings
(hepatic failure, fever), on biological data showing biologicalMehdi Oua¨ ıssi et al. 3
hepatic tests disturbances, and on CT scan ﬁndings. In the
distantpostoperativecourse,patientswerefollowedclinically
and by CT scan at 3, 6, and 12 months.
Post operative hospital stay and early outcome, were
assessed. Surgical and/or medical complications were regis-
tered and classiﬁed as either minor or major. Postoperative
pancreatic ﬁstula was deﬁned such as an international study
group deﬁnition [5]. All pancreatic ﬁstulas were deemed to
be a major surgical complication. Biliary ﬁstula was deﬁned
as biliary staining from drainage ﬂuid. Pancreatic and/or
biliary ﬁstulas were treated by octreotide and antibiotics
administration, or surgery if required. Postoperative gastric
atony was deﬁned by the need of inserting a nasogastric tube
over day 4 or as delayed oral food intake after postoperative
day 8. Mortality was deﬁned as death occurring in the course
of the hospitalization or within 3 months after discharge.
2.6. Studyendpoint
Primary end points included postoperative survival, postop-
erative complications, and length of hospital stay.
2.7. Statisticalanalysis
Statistical analyses were conducted using SPSS version 13.0.1
(SPSS Inc, Ill, USA). Association between qualitative vari-
ables was assessed with chi-square test (or Fisher exact test,
as appropriate). Means or median of continuous variables
were analyzed by Student’s t-test. Results of parametric and
nonparametric data were expressed as mean (±SD) and
median(±SD),respectively.Allvariablesweredichotomized.
Conﬁdence intervals were set at 95%. Actuarial survival was
analyzedbyKaplanMeiermethodandthesurvivaldiﬀerence
was compared by log rang test. A value for P<. 05 was
considered to be statistically signiﬁcant.
3. RESULTS
Between 1996 and 2006, 27 patients underwent portal
venous resection in the course of a pancreatic resection for
tumor. There were 15 males; mean age was 66 ± 9 (45–
81) years old. Most of the patients were operated on for
malignant tumors, pancreatic duct carcinoma (n = 25), and
cholangiocarcinoma (n = 1), and in one case only for a
pseudotumoral chronic pancreatitis (n = 1). Twenty seven
PDswereperformed.Preoperative risks wereevaluatedusing
the American Society Association (ASA) score. Most of the
patients were ASA I or II (n = 11, n = 13), others were
ASA score III (n = 3). Twelve patients had preoperative
endoscopic bilary derivation.
Thirteen (48%) patients underwent a pylorus preserving
PD, others (52%) underwent a standard PD. Mean time of
the PD resection was 400 ± 108 minutes. Venous lateral
resection was carried out using lateral venorrhaphy in 24
patients (89%); it was localized 1cm above or on SMV
conﬂuent (n = 24), on the conﬂuent (n = 12). In one case,
we used autologous venous graph for a type II resection. For
resections III and IV, primary end-to-end anastomosis, in
one case, and PTFE graft were conducted twice. All types
Table 2: Morbidity and mortality for all patients with venous
resection.
Group
Postoperative stay (days) 19 ±9
Postoperative in intensive care unit stay (days) 3 ± 4
Postoperative death 3 (11%)
Overall number of patients with complications 13 (48%)
Major surgical complications 8 (30%)
Thrombosis rate 7 (26%)
Hemorrhagic rate 4 (15%)
Reoperation 4 (15%)
Minor surgical complications 5 (18.5%)
Gastric atony 5 (18.5%)
Medical morbidity 1 (4%)
Embolism pulmonary 1 (4%)
Blood transfusion 16 (57%)
of resections are summarized in Table 1.O v e r a l lm o r t a l i t y
was 11%. Overall morbidity was 13 (48%), including 7
(26%) cases of thrombosis, 4 (14%) cases of hemorrhagic
complications, and one late pancreatic ﬁstula successfully
treated by radiological drainage. There were 5 (18%) cases
of gastric atony. Sixteen (57%) patients required blood
transfusion. The length of the hospitalization stay was 19±9
days (Table 2).
3.1. Thrombosiscomplication
The most common perioperative complication was throm-
bosis which occurred in 7 patients (25%). It was diagnosed
on clinical ﬁndings: all patients had fever, ascite, and
mental troubles, on biological data: hepatic biological data
increased 5 times the normal level in all the cases. CT scan
was performed in 5 cases of thrombosis showing a total
portal vein occlusion. Thrombosis occurred at mean day
4 and was associated to a hemoperitoneum in two cases.
Surgical treatment consisted in thrombectomy and drainage
of the hemoperitoneum. Despite this treatment, total portal
vein thrombosis persisted and curative anticoagulation was
continued for these two patients. One of them died after
another surgicalcontrolwith a newthrombectomy at day 18.
Three patients were successfully treated by curative
anticoagulation. After six months, CT scan showed a persist-
ing thrombosis implying the persistence of anticoagulation
treatment. Twopatients died of venous mesenteric infarction
despite a surgical control at days 1 and 10. Among 7 cases
of thrombosis, three deaths occurred after type II (n = 2)
or type IV (n = 1) resection. Among them four patients
received curative anticoagulant treatment. At the end of
follow up, there was no more thrombosis or occluded
anastomosis than the ﬁrst cast.
3.2. Hemorrhagecomplication
Four patients had hemorrhagic complications requiring in
all cases a surgical control. A portal vein thrombosis was4 Gastroenterology Research and Practice
associated twice with a hemorrhagic complication. Three
patients received curative anticoagulant therapy. Surgical
treatmentofthesehemorrhagesneededlavage,drainage,and
thrombectomy in case of portal thrombosis.
3.3. Long-termoutcome
Mean of follow-up was 23 ± 31 months. Once the early
postoperative course was achieved, no more cases of portal
thrombosis occurred. There was no more thrombosis or
occluded anastomosis than the ﬁrst cast. Median disease-free
survival was 16 months.
4. DISCUSSION
Although PD oﬀers the only chance of cure for patients
with adenocarcinoma of the pancreas, questions have arisen
regarding the indication, safety, and outcomes of patients
undergoing extended resections for locally advanced disease
[6]. While a previous study demonstrated an overall survival
beneﬁt after pancreatic resection without an increase of
morbidity and mortality rates [7–9], high mortality rate
was reported for patients with portal vein thrombosis [10–
13]. Few studies have focused on diﬀerent types of surgical
venous resections and diﬀerent modes of reconstruction of
the portal vein [6–14].
Few studies presented a radiological classiﬁcation in
order to predict the involvement of PV or SMV. Moreover,
Nakao’s report showed that macroscopic ﬁndings (classiﬁed
into types A, B, C, or D according to preoperative ﬁndings
on the portal phase of superior mesenteric angiography)
were correlated with the histological invasion grades [15–
17].However,thisclassiﬁcationwasbasedonangiographyor
CT scan. In contrast, the necessity of curative anticoagulant
therapy was evaluated by this preoperative classiﬁcation.
Moreover, our classiﬁcation of resection and reconstruction
permitted us to deﬁne the impact of resection of conﬂuent
and the modiﬁcation of blood ﬂow.
In this series, PD with venous resection was most com-
monly performed for pancreatic carcinoma. Most patients
(89%) underwent a lateral venous resection with recon-
struction by lateral venorrhaphy. Venous thrombosis rate
reached 0%, 38%, and 100% for type I, II, and IV resections,
respectively. One lateral venorrhaphy needed a patch of
saphenous vein. Thrombosis occurred early after surgery,
with an acute setting; no case of thrombosis appeared
secondarily, at distance from the surgical removal of the
tumor (after 6 months of follow-up). This result was in
agreement with Leach’s study which reported a thrombosis
rate of 25% [10].
Moreover, in case of type II resection, patients with a
p o r t a lr e s e c t i o nl e n g t ho v e r2c m ,o rw i t hP T F Er e c o n s t r u c -
tion, received anticoagulation with intravenous heparin. In
Leach’sstudy,thrombosisrateraisedto25%despitetheonset
of a lasting treatment by low dose of aspirin [10].
This systematic onset of anticoagulation did not protect
against venous thrombosis. These poor results were in
accordance with Smoot’s study which showed no diﬀerence
in the rate of portal thrombosis between patients undergoing
anticoagulant therapy and those without such treatment
(P = .65) [6]. These results were conﬁrmed in Carrere’s
study which demonstrated that only two cases of thrombosis
occurred in patients under curative heparinotherapy [14].
Hemorrhagic complication increased after PD and anti-
coagulation. In Carrere’s study, hemorrhage complications
occurred after resection followed by postoperative curative
anticoagulation. It required the immediate interruption of
the anticoagulant therapy [14]. In our study, hemorrhage
complicationsrequired4reinterventions.Infact,thrombosis
appeared to be more aﬀected by the type of reconstruction
rather than by the anticoagulant treatment.
Lateral resection with lateral venorrhaphy on the conﬂu-
ent(SMV)mustbeavoidedandreplacedbyacircumferential
resection with end-to-end anastomosis which appears to be
the best technique. According to Nakao and Fortner, the
defect of the portal venous system is repaired by pushing the
base of the small bowel mesentery upwards and achieving an
end-to-end anastomosis of the superior mesenteric vein to
the portal vein [18, 19].
If the defect overreaches 7cm or when mobilization of
the base bowel is insuﬃcient or not achievable, Smoot’s
technique using left renal vein should be preferred [20].
This technique allows staying in the same operative ﬁeld;
moreover, caliber and thickness of the venous renal wall are
similar to those of the portal vein. According to Mitsuta’s
study, reimplantation of the SV must take into account the
direction of its ﬂow [21].
In conclusion, after portal vein resection achieved in
the course of a PD, a lateral resection and reconstruction
with venorrhaphy should be chosen only when located 1cm
above the splenomesenteric conﬂuent. When resection of
conﬂuent is required, circumferential resection with end-to-
end anastomosis should be achieved. If this type of recon-
struction appears to be impossible, the use of a PTFE graft
must be avoided and the left renal vein can be a warranty
usedtocarryoutthevenousreconstruction.Whatevermight
be the technical choice of venous reconstruction, curative
postoperativeanticoagulationdoesnotpreventeﬃcientlythe
onset of thrombosis.
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